We are pleased to announce that Suzhou Connect Biopharma has established a wholly owned subsidiary, Australia Pty Ltd, in Melbourne, Australia on the 18th of July 2014. The establishment of our Australian subsidiary is an important strategic step in our operation. It will allow us to better execute the development of our clinical pipeline by working with the top quality clinical study centers and related CROs in the Australia.
康乃德是一家拥有临床阶段产品、全球化布局的生物医药公司,通过自主研发的T细胞功能调节平台开发创新疗法,从而改善炎症性免疫疾病患者的生活品质。
© 2021 苏州康乃德生物医药有限公司,版权所有